2024 was a tough year for the biopharma industry, with several companies cutting hundreds or even thousands of employees. Follow along as BioSpace tracks job cuts and restructuring initiatives throughout 2025.
While layoffs slowed in the second half of 2024, biopharmas including Bayer, Bristol Myers Squibb and Johnson & Johnson cut hundreds or even thousands of employees over the course of the year.
Other notable greenlights this year include Bristol Myers Squibb’s Cobenfy, the first novel therapeutic for schizophrenia in 35 years, and Madrigal Pharmaceuticals’ Rezdiffra, the first-ever treatment for MASH.
BioSpace will be in attendance at the American Society of Gene & Cell Therapy’s 27th annual meeting, along with thousands of others. Stay with us for updates throughout the week.
If you’re a life sciences professional in the Genetown hotbed (Boston, Cambridge and the surrounding areas of Massachusetts) and are looking for your next challenge, take a look at these companies hiring on BioSpace.
BioSpace continues to bring you the latest news and industry developments from the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. Stay tuned!
